$SGTM Receives Annual Mulch Product Order from 7-Eleven Stores, Held by $SVNDY

ORLANDO, Fla., Oct. 29, 2020 (GLOBE NEWSWIRE) — Sustainable Green Team, Ltd. (OTC: SGTM) (“SGTM” or the “Company”), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, today announces that its wholly owned subsidiary Mulch Manufacturing, Inc. will be supplying quality mulch products and services to 7-Eleven stores throughout the Midwest U.S. and western New York, slated to commence in 2021. The contract was received a week after the Company closed an annual mulch supply contract with the City of Vero Beach, Florida .

7-Eleven, Inc. is an American international chain of convenience stores, headquartered in Dallas, Texas. The chain was founded in 1927 as an icehouse storefront in Dallas. After 70% of the company was acquired by Japanese affiliate Ito-Yokado in 1991, it was reorganized as a wholly owned subsidiary of Seven-Eleven Japan Co., Ltd. in 2005 and is now held by Chiyoda, Tokyo-based Seven & I Holdings Co., Ltd. (OTC:SVNDY). As of July 2020, 7-Eleven, Inc. operates, franchises and licenses 71,100 stores in 17 countries. In August of 2020, 7-Eleven, Inc. announced one the largest M&A deals of the year, a $21 billion purchase of Speedway from Marathon Petroleum Corp. (NYSE: MPC) .

SGTM’s CEO and Director Tony Raynor states, “Thanks to our VP of Sales Paul Stolly, we continue to secure major international chain accounts to start 2021 strong, commencing with 7-Eleven, Inc.’s Midwest U.S. and western New York locations. This allows us to build brand integrity and supply for future expansion as we progress.”

About Sustainable Green Team, Ltd. (SGTM)

Sustainable Green Team, Ltd. (“SGTM”), through its subsidiaries, provides tree services, debris hauling and removal, biomass recycling, mulch manufacturing, packaging and sales. The Company was established with the objective of providing a solution for the treatment and handling of tree debris that has historically been disposed of in landfills, creating an environmental burden and pressure on disposal sites around the nation. The Company’s solutions are founded in sustainability, based on vertically integrated operations that begin with collecting tree debris through its tree services division and collection sites and then, through its processing division, recycling and using that tree debris as a feedstock that is manufactured into a variety of organic, attractive, next-generation mulch products that are packaged and sold to landscapers, installers and garden centers. The Company plans to expand its operations through a combination of organic growth and strategic acquisitions that are both accretive to earnings and are positioned for rapid growth from the resulting synergistic opportunities identified. The Company’s customers include governmental, residential and commercial clients.

SGTM currently has two wholly owned subsidiaries to efficiently assess areas, recover, manufacture and distribute:

National Storm Recovery, LLC

National Storm Recovery, LLC (“NSR”) is composed of a team that has expertise in dangerous tree removal, debris hauling and debris management. The Company’s management team assesses storms by deploying its mobile command center to designated sites and then strategizing with its national partners, which include government agencies, prime contractors and subcontractors.

Central Florida Arborcare (“CFA”), a DBA of NSR, has spent more than 40 years perfecting its technique for proper tree care, removal and services. From tree removal, stump grinding and tree care to grapple hauling and storm recovery, CFA ensures properties remain safe and businesses can continue as usual.

To learn more please visit: https://www.centralfloridaarborcare.com

Mulch Manufacturing, Inc.

Mulch Manufacturing, Inc. (“MMI”), being vertically integrated, receives a large volume of wood fiber recovered from Central Florida Arborcare to feed raw material needs. MMI has the product line and distribution system to address a substantial customer base, which can be expanded.

To learn more please visit: https://mulchmfg.com

For additional information regarding SGTM’s operations, expansion plans and production facilities, view the Company’s presentation .

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, listing on the CSE, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will” and other similar expressions, are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance or achievements to differ materially from anticipated results, performance or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise. No information in this press release should be construed in any matter whatsoever as an indication of the future performance of the Company’s revenues, financial condition or stock price.

Company Contact:
Anthony Raynor
CEO & Director
407.886.8733 Office

Corporate Communications:
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

$PCSA Biomedical Engineer Invents Technique That May Help Improve Eyesight

$NETE The Benefits, Drawbacks of Buying Used Electric Vehicles

$GNPX Announces Conditional FDA Acceptance of Proprietary Name for Lead Drug Candidate

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has received conditional FDA acceptance of the proprietary name REQORSA(TM), its lead drug candidate for treatment of non-small cell lung cancer. The drug candidate was known previously by the laboratory designation GPX-001. The approval of the new name marks a critical branding milestone  for the company. Genprex’s REQORSA (pronounced “re-KORE-suh”) immunogene therapy features the company’s exclusive ONCOPREX(TM) nanoparticle delivery system that delivers cancer-fighting genes. The name will be resubmitted to the FDA for final review and approval after all required clinical trials are completed; that final approval is based on the FDA’s approval of the product candidate. The new name was based on FDA’s guidelines for the submission and evaluation of proprietary names. Genprex selected the name based on a comprehensive review of name candidates, including a study of healthcare practitioners across the country to guarantee accurate prescription and safety interpretation of the name. “We are very pleased to receive FDA’s conditional acceptance of our proprietary name, REQORSA, which is a necessary step toward being able to market our lead drug candidate for non-small cell lung cancer,” said Genprex president and CEO Rodney Varner in the press release. “This name approval also marks an important milestone in our overall branding strategy, giving us a unique, easily understood name people can associate with the Genprex brand and mission.”

To view the full press release, visit http://ibn.fm/H3ph0

About Genprex Inc.

Genprex is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, GPX-001 (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). GPX-001 has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. GPX-001 has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted fast track designation for GPX-001 for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with “EFGR” mutations whose tumors progressed after treatment with osimertinib alone. For more information, please visit the company’s website at www.Genprex.com

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

$CRTD Announces Board Appointment of Seasoned Securities Attorney

Creatd (NASDAQ: CRTD, CRTDW), the parent company of Vocal, a robust, proprietary technology platform for digital creators, today announced the appointment of LaBrena Jones Martin to its Board of Directors, where she will chair its Corporate Governance and Nomination Committee and serve on the Compensation and Audit Committees. Martin brings extensive legal experience at the senior management level, spanning nearly 40 years and encompassing all facets of corporate and securities law. “Over the years, it has been my privilege to work closely with LaBrena at Lehman and again at RBC, where we collaborated on many strategic, complex and mission-critical projects. She is not only a talented legal mind, but also has sharp business and management acumen,” Creatd’s Chairman of the Board, Mark Standish, said in the press release. “Creatd is well past the proof of concept and initial commercialization stages and, as a newly listed Nasdaq company, is now entering an anticipated growth momentum period. LaBrena has been a guiding force for several companies at this growth stage, and I believe she will be similarly instrumental in providing sound oversight to Creatd.”

To view the full press release, visit https://ibn.fm/iw0aJ

About Creatd Inc.

Creatd is the parent company and creator of Vocal, a robust and proprietary technology platform that uniquely serves creators, brands and audiences by providing long-form storytelling tools, advanced social features and monetization opportunities. Since launching in December 2016, Vocal has become home to approximately 750,000 content creators and over 4,000 paid subscribers of its recently launched Vocal+ membership program, attracting over 10 million monthly visitors across its network of 34 wholly owned and operated niche communities. For more information about Creatd and its Vocal platform, visit www.Creatd.com and www.Vocal.media.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

$CNSP Announces Completion of Drug for Clinical Trials

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has through its European manufacturer, BSP Pharmaceuticals S.p.A. (“BSP”), finished manufacturing its lead drug candidate for upcoming Phase 2 clinical trials. Berubicin is CNSP’s lead drug candidate for the treatment of glioblastoma multiforme (“GBM”), an aggressive form of brain cancer that is incurable. With the completion of the manufacturing, CNS Pharmaceuticals is now ready to kick off its planned Phase 2 clinical trials and file an Investigational New Drug Application (“IND”). CNSP contracted with two manufacturers on two continents — BSP Pharmaceuticals S.p.A. and Pharmaceutics International Inc. (“Pii”) — to alleviate any potential risks. The decision also allowed the company to expand its supply chain and prepare for more convenient availability of Berubicin. Both BSP and Pii have completed manufacturing the drug. “We are pleased to continue to execute upon our dual-track drug product manufacturing strategy, as both our U.S. manufacturer, Pii, and European manufacturer, BSP, have now completed production of Berubicin Drug Product,” said CNS Pharmaceuticals CEO John Climaco in the press release. “The completion of the manufacturing process at both locations represents a key milestone for us and will further support our efforts to file an IND during the fourth quarter of this year. We are encouraged by our continued execution upon our pre-trial initiatives, and believe we remain positioned to initiate a U.S. Phase 2 trial for Berubicin during the first quarter of 2021.”

To view the full press release, visit http://ibn.fm/9Dyby

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. By the end of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the United States, while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. The company’s second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information about the company, please visit www.CNSPharma.com

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at http://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

$CNPOF PharmHouse Begins Sale and Investor Solicitation Process

TORONTO , Oct. 29, 2020 – PharmHouse Inc. (” PharmHouse “), Canopy Rivers Inc.’s (” Canopy Rivers “) (TSX: RIV) (OTC: CNPOF) 49%-owned joint venture, has received approval from the Ontario Superior Court of Justice to commence its Sale and Investor Solicitation Process (” SISP “). The SISP is intended to solicit interest in, and opportunities for, a sale of, or investment in, all or part of PharmHouse’s assets or business. This may include a restructuring, recapitalization, or other form of reorganization of PharmHouse’s business and affairs.

PharmHouse has engaged BMO Capital Markets (” BMO “) to lead the SISP with oversight from Ernst and Young Inc. (” E&Y “), the monitor in PharmHouse’s Companies’ Creditors Arrangement Act (” CCAA “) proceedings.

The phase 1 deadline for offers under the SISP will be on or about November 30, 2020 . Interested parties should contact BMO using the contact information below. Further information on the SISP and bidding, as well as all documents relating to PharmHouse’s CCAA proceedings, can be found at http://www.ey.com/ca/pharmhouse .

SISP Advisor Contact Information
Ian Kilimnick
ian.kilimnik@bmo.com

Greg Meligrigoris
gregory.meligrigoris@bmo.com

BMO Capital Markets
100 King St. W, 4th Floor
Toronto , ON  M5X 1H3

About Canopy Rivers
Canopy Rivers is a venture capital firm specializing in cannabis with a portfolio of 18 companies across various segments of the cannabis value chain. We believe that bringing together people, capital, and ideas raises the potential of the entire cannabis industry. By leveraging our industry insights, in-house expertise, and thesis-driven approach to investing, we aim to provide shareholders with exposure to specialized and disruptive cannabis companies. Our mission is to invest in innovators across the cannabis value chain, help them grow, and ultimately create value by guiding these companies towards a monetization event. Together with our portfolio, we are helping build the cannabis industry of tomorrow, today.

Forward Looking Statements
This news release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of Canopy Rivers with respect to future business activities and operating performance. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes information regarding the timing and potential outcomes of the SISP.

Investors are cautioned that forward-looking information is not based on historical fact but instead reflects management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although Canopy Rivers believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of Canopy Rivers. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: regulatory and licensing risks; changes in cannabis industry growth and trends; changes in general economic, business and political conditions, including challenging global financial conditions and the impact of the novel coronavirus pandemic; potential conflicts of interest; the regulatory landscape and enforcement related to cannabis, including political risks and risks relating to regulatory change; risks associated with the termination, renegotiation and enforcement of material contracts; credit, liquidity and additional financing risks; changes in applicable laws; compliance with extensive government regulation, including Canopy Rivers’ interpretation of such regulation; public opinion and perception of the cannabis industry; divestiture risks; competition risks; and the risk factors set out in Canopy Rivers’ annual information form dated June 2, 2020 , filed with the Canadian securities regulators and available on Canopy Rivers’ profile on SEDAR at www.sedar.com .

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although Canopy Rivers has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. Canopy Rivers does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

$AZRX Talks Porcine Usage, Producing Synthetic Alternative

AzurRx BioPharma (NASDAQ: AZRX), a New York-based biopharmaceutical company specializing in the development of therapeutic proteins for the treatment of patients with gastrointestinal disorders, recently talked about its usage of porcine (pig) products in its production of pharmaceuticals and medicinals. Included in the discussion was a look at the disadvantages of such usage. AzurRx noted that pigs have been used for centuries in medical research and development; in fact, one study noted that pigs had been used in an estimated 20 medications and pharmaceuticals  including six for the pancreas, which are of particular interest for AZRX. There are downsides to such usage, the company noted, including supply chain, concentration and purity issues. Because of these issues, AzurRx is hoping  to develop synthetic replacement products. One of AZRX’s most promising treatments is MS1819, a lead product candidate being studied for the treatment of exocrine pancreatic insufficiency (“EPI”) associated with cystic fibrosis (“CF”) and chronic pancreatitis (“CP”). The company is currently involved in several clinical trials for the drug, including two trial sites that were recently activated in Turkey. “We are truly pleased and encouraged by the interest in our expanding global Phase 2 Combination Trial,” AzurRx chief medical officer Dr. James Pennington stated in the press release. “The recently reported interim data suggests promising results, and the full data readout is expected in the second quarter of next year. Our investigators in Turkey have been extremely diligent in driving the startup of this trial in a very efficient and effective manner, and we look forward to our continued work with them.”

To view the full press release, visit: https://ibn.fm/dZk2B

About AzurRx BioPharma Inc.

AzurRx BioPharma is a biopharmaceutical company specialized in the research and development of nonsystemic biologics for gastrointestinal disorders. The company is focused on the development of its lead drug candidate, MS1819. AzurRx is currently conducting two Phase 2 clinical trials of MS1819: the OPTION 2 monotherapy trial and the combination therapy trial, consisting of MS1819 in conjunction with porcine-derived pancreatic enzyme replacement therapy, the current standard of care. The company is headquartered in New York, NY, with clinical operations in Hayward, California. For more information, visit the company’s website at www.AzurRx.com.

NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at http://ibn.fm/AZRX

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

$WRTC Reports Third Quarter 2020 Results, Tom Smith Appointment to Interim CEO

Wrap Technologies, Inc. (Nasdaq: WRTC) (the “Company”), an innovator of modern policing solutions, today announced results for its third quarter ended September 30, 2020. In addition, in a separate announcement today, the Company announced a leadership change as Tom Smith was named interim CEO by the board of directors.

Third Q uarter 2020 Summary

Net Sales of $1.0 million, G rowth of 275%
Gross Margin of 32 %
Cash, Cash Equivalents and Short-Term Investments of $45.1 million
Backlog at $ 1.1 million

Management Commentary – Tom Smith , I nterim CEO
“During the third quarter, we continued to take advantage of the considerable visibility that safer police solutions have received from the government, media and communities over the past two quarters. This was evident in our financial performance as we again generated sequential revenue growth while gross margins remained stable. Our team was pleased to exceed $1 million in sales for the quarter for the first time. Over 100 new agencies were trained in Q3 and we now have over 1,100 officers at over 300 agencies certified to train their departments. We are executing our long-term strategy as planned. We remain uniquely positioned to increase sales of our BolaWrap product, which is effective and affordable. We remain intensely focused on driving sales by continuing to execute our strategy and refining our approach to engage police agencies across the globe.”

⁽¹⁾ As compared to the prior year period.

THIRD QUARTER 20 20

Net Sales

• Generated revenue of $1.0 million during 3Q20.
• 21% sequential increase as compared to 2Q20 ($0.8 million).
• Generated $2.5 million of revenue on a year-to-date basis during 3Q20. This reflects the continual ramp of our business at this early stage.
• We continue to see recovery in our ability to conduct product demonstrations and training during the COVID pandemic. Both of these are important to police agency adoption, which has been impacted by COVID since March. In addition, many police agencies have had to divert resources to community protests and demonstrations, which has also negatively impacted our sales activity in recent quarters. We expect both of these issues to improve in the future, but we cannot predict when.

Gross Profit

• Generated $0.3 million of gross profit for 3Q20.
• Gross margin was 32% for 3Q20 and comparable to 2Q20.
• Generated $0.9 million of gross profit on a year-to-date basis for 3Q20. Our gross margin year-to-date 3Q20 is 34%.
• We expect our gross margins to continue to be fluid as we ramp our revenue base.
• Based on initiatives we are implementing, we believe that our long-term target of over 40% gross margins is achievable.

Selling , General and Administrative (SG&A) Expense

• SG&A expense increased $1.4 million in 3Q20 as compared to 3Q19.
• This was driven primarily by $0.6 million of employee costs as we ramp our sales force and training teams, $0.4 million of increased marketing and promotion, and $0.1 million related to increased public company reporting expense.
• SG&A expense increased $3.4 million on a year-to-date basis, which is reflective of our investment in our business during our initial ramp of sales and production.

Inventory

• Inventory decreased slightly during the quarter, from $2.1 million at 2Q20 to $2.0 million at 3Q20.
• This was related to finished goods growth of $0.1 million offset by $0.2 reduction in raw materials from 2Q20 to 3Q20.

Cash, Marketable Securities and Debt

• Cash, Cash Equivalents and Short-term Investments grew to $45.1 million at 3Q20 as compared to $35.4 million at 2Q20, reflecting cash generated from the exercise of warrants during the quarter.
• This represents 91% of total assets.
• In May 2020, we took advantage of a Paycheck Protection (PPP) Loan in the amount of $0.4 million. We filed an application for forgiveness in October 2020 since we believe all proceeds were used consistent with the published rules related to the PPP program.

Outlook

We continue to expect near-term headwinds to our growth as international travel remains limited and police agencies continue to face significant demonstration, protests and civic unrest. We expect these factors to continue through the rest of 2020 then soften as we proceed through 2021.

Webcast and Earnings Conference Call

As announced on October 15, 2020, the Company will host a live Zoom video webcast for investors and other interested parties beginning at 4:30 p.m. Eastern Time on Thursday, October 29, 2020. The call will be hosted by Tom Smith, Interim CEO and President, Jim Barnes, CFO Secretary and Treasurer, and Paul Manley, VP of Investor Relations.

WEBCAST LINK: https://us02web.zoom.us/webinar/register/WN_4KF5MDTcQDu8TTXUSLjwoA

Participants may access the live webcast by visiting the Company’s Investor Relations page at www. wraptechnologies .com . A webcast replay of the call will be available on the Company’s Investor Relations page within 24 hours of the live call ending.

Contact

Investors and Media:
Paul M. Manley
Vice President of Investor Relations
(612) 834-1804
pmanley@wraptechnologies.com

A bout Wrap Technologies

Wrap Technologies is an innovator of modern policing solutions. The Company’s BolaWrap 100 product is a patented, hand-held remote restraint device that discharges an eight-foot bola style Kevlar® tether to restrain an individual at a distance from 10 to 25 feet. Developed by award winning inventor Elwood Norris, the Company’s Chief Technology Officer, the small but powerful BolaWrap 100 assists law enforcement in safely and effectively deescalating encounters, especially those involving an individual in crisis. BolaWrap 100 has already been used to safely apprehend suspects without injury in a number of cities including Los Angeles, Sacramento, Fresno, Bell, Albuquerque, Minneapolis, West Palm Beach, Fort Worth, and Oak Ridge. For information on the Company, please visit www.wraptechnologies.com.

Use of Non-GAAP Information

Included in this press release are non-GAAP operational metrics regarding agencies, training, backlog and amounts of non-cash stock-based compensation expense, which the Company believes provide helpful information to investors with respect to evaluating the Company’s performance. The Company considers backlog as an indicator of future revenues and uses it to support production planning. Backlog is a measure of purchase orders received that have not been shipped, but which the Company expects to ship within the next 12 months. Distributor and customer orders for future deliveries are generally subject to modification, rescheduling or in some instances, cancellation in the normal course of business.

Trademark Information

BolaWrap and Wrap are trademarks of Wrap Technologies, Inc. All other trade names used herein are either trademarks or registered trademarks of the respective holders.

Cautionary Note on Forward-Looking Statements – Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to: statements regarding the Company’s overall business; total addressable market; and, expectations regarding future sales and expenses. Words such as “expect”, “anticipate”, “should”, “believe”, “target”, “project”, “goals”, “estimate”, “potential”, “predict”, “may”, “will”, “could”, “intend”, and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Moreover, forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the Company’s ability to successful implement training programs for the use of its products; the Company’s ability to manufacture and produce product for its customers; the Company’s ability to develop sales for its new product solution; the acceptance of existing and future products; the availability of funding to continue to finance operations; the complexity, expense and time associated with sales to law enforcement and government entities; the lengthy evaluation and sales cycle for the Company’s product solution; product defects; litigation risks from alleged product-related injuries; risks of government regulations; the business impact of health crises or outbreaks of disease, such as epidemics or pandemics; the ability to obtain export licenses for counties outside of the US; the ability to obtain patents and defend IP against competitors; the impact of competitive products and solutions; and the Company’s ability to maintain and enhance its brand, as well as other risk factors mentioned in the Company’s most recent annual report on Form 10-K, quarterly report on Form 10-Q, and other SEC filings. These forward-looking statements are made as of the date of this press release and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

Also Today,

Wrap Technologies, Inc. (Nasdaq:WRTC) announced that its board of directors named Tom Smith, as its Interim CEO, effective October 27, 2020.  Marc Thomas stepped down from the CEO role, and has been appointed to the newly created position of Chief Government Affairs Officer.

“We are very excited for Tom to assume the additional responsibilities of Interim CEO as we continue to execute on our mission,” said Scot Cohen, Executive Chairman of the Board. “Our goal is to have remote restraint become standard for every police officer worldwide. With 27 years of industry experience, Tom energizes the entire organization and knows the industry extremely well.” Cohen continued, “Marc’s background, skills and passion will help drive change within government entities in this new role during these unprecedented times. As a White House Fellow with an exemplary military background and legislative experience, Marc’s ability to work with government leaders will enhance our position with police and security forces adoption of our technology and training which de-escalates conflict.”

“Our company takes great pride in serving our stakeholders, communities and people who protect us daily,” said Tom Smith, Interim CEO and President. “Now more than ever, collaboration between communities and law enforcement is needed. The BolaWrap, through our technology and training, fills an important void for law enforcement agencies that de-escalates without using pain compliance tools during the apprehension process. Our time is now, and my top priority is to continue to ramp growth. We are still in the early stages with an enormous opportunity ahead of us. I thank Scot and the rest of the board for the opportunity and privilege to lead this team,” concluded Smith.

CONFERENCE CALL

As announced on October 15, 2020, the Company will host its 3Q earnings call via a live Zoom video webcast for investors and other interested parties beginning at 4:30 p.m. Eastern Time today (Thursday, October 29, 2020). The call will be hosted by Tom Smith, interim CEO, Jim Barnes, CFO, and Paul Manley, VP of Investor Relations.

WEBCAST LINK: https://us02web.zoom.us/webinar/register/WN_4KF5MDTcQDu8TTXUSLjwoA

Participants may access the live webcast by visiting the Company’s Investor Relations page at www. wraptechnologies .com . A webcast replay of the call will be available on the Company’s Investor Relations page within 24 hours of the live call ending.

A bout Wrap Technologies

Wrap Technologies is an innovator of modern policing solutions. The Company’s BolaWrap 100 product is a patented, hand-held remote restraint device that discharges an eight-foot bola style Kevlar® tether to restrain an individual at a distance from 10 to 25 feet. Developed by award winning inventor Elwood Norris, the Company’s Chief Technology Officer, the small but powerful BolaWrap 100 assists law enforcement in safely and effectively deescalating encounters, especially those involving an individual in crisis. BolaWrap 100 has already been used to safely apprehend suspects without injury in Los Angeles, Sacramento, Fresno, Bell, Albuquerque, Minneapolis, West Palm Beach, Fort Worth, and Oak Ridge. For information on the Company, please visit www.wraptechnologies.com.

Trademark Information

BolaWrap and Wrap are trademarks of WRAP Technologies, Inc. All other trade names used herein are either trademarks or registered trademarks of the respective holders.

Cautionary Note on Forward-Looking Statements – Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to: statements regarding the Company’s overall business; total addressable market; and, expectations regarding future sales and expenses. Words such as “expect”, “anticipate”, “should”, “believe”, “target”, “project”, “goals”, “estimate”, “potential”, “predict”, “may”, “will”, “could”, “intend”, and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Moreover, forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the Company’s ability to successful implement training programs for the use of its products; the Company’s ability to manufacture and produce product for its customers; the Company’s ability to develop sales for its new product solution; the acceptance of existing and future products; the availability of funding to continue to finance operations; the complexity, expense and time associated with sales to law enforcement and government entities; the lengthy evaluation and sales cycle for the Company’s product solution; product defects; litigation risks from alleged product-related injuries; risks of government regulations; the business impact of health crises or outbreaks of disease, such as epidemics or pandemics; the ability to obtain export licenses for counties outside of the US; the ability to obtain patents and defend IP against competitors; the impact of competitive products and solutions; and the Company’s ability to maintain and enhance its brand, as well as other risk factors mentioned in the Company’s most recent annual report on Form 10-K, quarterly report on Form 10-Q, and other SEC filings. These forward-looking statements are made as of the date of this press release and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

Contact

Investors and Media:
Paul M. Manley
Vice President of Investor Relations
(612) 834-1804
pmanley@wraptechnologies.com

Rritual Mushrooms Inc.’s New Line of Elixirs Provides ‘Daily Dose’ with Powerful Benefits

October 27, 2020

$VTGN InvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast Featuring VistaGen Therapeutics Inc. CEO Shawn Singh

LOS ANGELES, Oct. 27, 2020 — via InvestorWire – InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Stock2Me Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

The Stock2Me Podcast features a fascinating array of companies and individuals, many of whom are actively revolutionizing age-old business practices within their respective markets. Stock2Me’s latest podcast features Shawn Singh, CEO of VistaGen Therapeutics Inc. (NASDAQ: VTGN) .

“Throughout the many years I’ve been in the [biopharma] space, I really haven’t been satisfied with the treatment alternatives that have been available to people all around the world who are suffering from mental illness, especially anxiety and depression,” Singh stated during the interview. “VistaGen provides, I think, an opportunity for tremendous excitement, given what we’re working on in our pipeline. We have three drug candidates focused on trying to go beyond the current standard of care for anxiety, depression and other CNS, or central nervous system, disorders.”

VistaGen’s lead drug candidate, PH94B, is a first-in-class neuroactive nasal spray that’s currently being developed as an acute treatment for anxiety in adults with Social Anxiety Disorder (SAD). Fast-acting (10-15 minutes), non-systemic and non-sedating in Phase 2 clinical studies, PH94B has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA), positioning it to potentially become the first FDA-approved fast-acting acute treatment for adults with SAD, if planned Phase 3 studies are successful.

The company’s development pipeline also includes PH10, an investigational synthetic neuroactive nasal spray being initially developed as a potential fast-acting, non-sedating, non-addictive new generation treatment of major depressive disorder (MDD), and AV-101, an oral prodrug of 7-chloro-kynurenic acid (7-Cl-KYNA) with potential to serve as an innovative treatment for MDD and multiple neurological indications where current therapies are unsatisfactory.

“What’s exciting about all of these and where we see some game-changing potential in the landscape is the way they work and how fundamentally different we think each of them is from current treatment alternatives,” Singh continued. “The way a drug works and the way it works in the brain for a neuropsychiatric indication is critical. … We’ve got, I think, an opportunity, based on the drug development programs we’ve got moving, to really swing the paradigm into a different direction where patients can learn faster whether a drug is going to deliver a benefit, and they’re not going to have to, during that period, worry as much about the types of side effects and safety concerns that are associated with current therapies.”

Join InvestorBrandNetwork’s Stuart Smith and VistaGen’s Shawn Singh in exploring how VistaGen is working to redefine the standard of care for people suffering from anxiety, depression and other CNS disorders through the continued advancement of its promising development pipeline.

To hear the whole episode and subscribe for future episodes, visit: https://podcast.stock2me.com

The latest installment of The Stock2Me Podcast continues to reinforce InvestorBrandNetwork’s commitment to the expansion of its robust network of brands, client partners, followers and the growing IBN Podcast Series . For more than 15 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies .

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About InvestorBrandNetwork

The InvestorBrandNetwork (“IBN”) consists of financial brands introduced to the investment public over the course of 15+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through NetworkNewsWire (“NNW”) and its affiliate brands, IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) a total news coverage solution.

For more information about IBN, visit https://www.InvestorBrandNetwork.com .

Please see full terms of use and disclaimers on the InvestorBrandNetwork website, applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

$MEDS to Announce Q3 2020 Results, Host Conference Call

Trxade Group (NASDAQ: MEDS), an integrated drug procurement, delivery and health-care platform, will release financial results for the third quarter ended September 30, 2020, after market close on Monday, October 26, 2020. According to the update, Trxade management will host a conference call to discuss the results at 5:00 p.m. Eastern Time on Monday, October 26, 2020. The call will conclude with Q&A from participants. Interested parties may join the call by dialing 1-877-425-9470 (U.S.) or 1-201-389-0878 (International) and entering conference ID: 13711397. To register for the event, visit the following webcast link: https://ibn.fm/E4I4K. Attendees are asked to dial in at least 10 minutes prior to the call to ensure timely participation.

To view the full press release, visit http://ibn.fm/1Wo4Z

About Trxade Group Inc.

Headquartered in Tampa, Florida, Trxade Group is an integrated drug procurement, delivery and health-care platform that fosters price transparency, thereby improving profit margins for both buyers and sellers of pharmaceuticals. Trxade Group operates across all 50 states with the central mission of making health-care services affordable and accessible. Founded in 2010, Trxade Group is comprised of three synergistic operating platforms: (1) the Trxade B2B trading platform with around 11,800 registered pharmacies; (2) Integra Pharma Solutions, Trxade Group’s virtual wholesale division; and (3) the Bonum Health platform offering affordable telehealth services. For additional information, please visit www.Trxade.com and www.BonumHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

$POAI CEO Provides Company Updates on Exclusive NNW Audio Interview

Predictive Oncology (NASDAQ: POAI) CEO Carl Schwartz was featured in a recent NetworkNewsWire (“NNW”) audio interview. During the interview, Schwartz provided updates on the company’s subsidiaries, noted recent company milestones and outlined near-term goals. POAI, a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has four wholly owned subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Schwartz focused the discussion on these companies, offering brief insight into the operations of Skyline Medical and noting that the purpose of TumorGenesis was to develop a lab media to replace rats and mice in the scientific industries and in the testing of tumors, which the company has done. The next step, said Schwartz, is to get the kits out so people can use it, an effort that is “coming along handsomely.” In addition, Schwartz discussed Soluble Biotech, POAI’s newest subsidiary. Schwartz noted that the company is two labs “that we put together” and moved into a research park, quadrupling the working space. Schwartz explained that “the technology used by Soluble is proprietary. These machines . . .  are the only machines of their kind. In the determination of solubility of products, they work wonders in that area.” Schwartz also discussed Helomics.

“The original basis of Helomics. . . was that physicians or hospitals would send their tumors to this company, and they would test the tumors with the known therapies of the day. . . . In that process, [Helomics] accumulated over 150,000 tumors overing over 137 different cancers. . . . That database is the largest of its kind in the world. . . .With that data, and the fact that we’ve sequenced these tumors, we have shown that we can provide quality information to anyone who needs it. There’s a lot going on at Helomics. We think we’ve validated the company. We’ve got assets that are one-of-a-kind in the world, and we think we are on our way to where we wanted to be when we first purchased this company a couple of years ago.”

To listen to the full interview, visit http://ibn.fm/xQQwT

To view the full press release, visit http://ibn.fm/MEFLq

About Predictive Oncology

Predictive Oncology operates through three segments (domestic, international and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Soluble Biotech.  Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. For more information about the company, please visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

$NETE EV Battery Makers Need to Consider Recycling Needs to Avert Waste Crisis

$DRIO Patent Suggests Apple Is Working on Smart Biomedical Glasses

$CNSP Comparison Between Saliva, Swab Coronavirus Tests

$AZRX Announces Positive Results in Ongoing Phase 2 Combination Therapy Trial with MS1819

AzurRx BioPharma (NASDAQ: AZRX), a clinical-stage biopharmaceutical company, recently announced positive results from the first five patients in its Phase 2 combination therapy trial of MS1819 for the treatment of severe exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis (“CF”). In the primary efficacy analysis, patients receiving MS1819 in combination with PERT therapy achieved a clinically meaningful improvement in the coefficient of fat absorption (“CFA”) at each of the three dose levels. No adverse safety events were reported and, additionally, patients showed improvements in the key secondary endpoints, including body weight, stool consistency and reductions in the number of bowel movements and the incidence of steatorrhea. “We are thrilled to see such consistently positive responses from these initial patients in our ongoing Phase 2 combination therapy trial with MS1819. EPI is a very challenging disease with many CF patients unable to achieve healthy nutrition even when using the maximum number of allowed or tolerated PERT capsules, especially those in the moderate-severe categories,” AzurRx CEO James Sapirstein said of the results. “We look forward to completing treatment of all patients and announcing top line data in 2021.”

To view the full press release, visit http://ibn.fm/G4kBU

About AzurRx BioPharma Inc.

AzurRx BioPharma is a biopharmaceutical company specializing in the research and development of nonsystemic biologics for gastrointestinal disorders. The company is focused on the development of its lead drug candidate, MS1819. AzurRx is currently conducting two Phase 2 clinical trials of MS1819: the OPTION 2 monotherapy trial, and the Combination therapy trial, consisting of MS1819 in conjunction with porcine-derived pancreatic enzyme replacement therapy, the current standard of care.  The company is headquartered in New York, NY, with scientific operations based in Langlade, France, and clinical operations in Hayward, California. For more information about the company, visit www.AzurRx.com.

NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at http://ibn.fm/AZRX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

$SGLB Announces Q3 2020 Financial Results

Sigma Labs (NASDAQ: SGLB), a leading developer of in-process quality assurance software for the commercial 3D metal printing industry, on Thursday released its financial and operational results for the third quarter ended September 30, 2020. “The third quarter of 2020 was about execution and laying the foundation for a successful 2021, and we are very pleased to have made significant progress in each of the strategic initiatives that we established at the beginning of the year,” Mark K. Ruport, president and chief executive officer of Sigma Labs, said in the press release. “On the financial front, our balance sheet expanded during the third quarter by $3.5 million from the exercise of preferred warrants from our January 2020 private placement of convertible preferred stock and warrants. This, paired with a continued reduction in cash burn, has better positioned Sigma to weather any macro-economic storms that may arise over the coming months and extends our cash runway well into 2021.”

To view the full press release, visit https://ibn.fm/ISZID

About Sigma Labs Inc.

Sigma Labs is a leading provider of quality assurance software to the commercial 3D metal printing industry under the PrintRite3D(R) brand. Sigma specializes in the development and commercialization of real-time monitoring solutions known as PrintRite3D for 3D metal advanced manufacturing technologies. PrintRite3D detects and classifies defects and anomalies real-time during the manufacturing process and informs the production manager of quality issues. Sigma Labs believes its software product will be a major catalyst for the acceleration and adoption of 3D metal printing. For more information, please visit www.SigmaLabsInc.com.

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

$NETE EV Makers Turn to SPACs for Easier Access to Stock Markets

$NETE Mullen Stand to Benefit from Decreasing EV Manufacturing Costs

SPAC Merger Fires Boosters for 180 Life Sciences’ Exploration in Unmet Medical Needs of Anti-inflammatories Space

Fast-Growing Michigan Market Next in Line for Gage Cannabis Co., IPO Planned for 2021

$CNSP Social Distancing, Masks May Not Be Enough to Prevent Coronavirus Infection

$CNSP Moves Closer to IND Filing as Manufacturing of Lead Drug Candidate Commences

$WTER Missouri Opens State’s First Medical Cannabis Dispensaries and Launches Sales

$WTER Forms New Partnership with KOA(R) and Yogi Bear’s Jellystone Park(TM) Camp-Resorts

The Alkaline Water Company (CSE: WTER) (NASDAQ: WTER), a producer of premium bottled alkaline and flavored-infused drinking waters and CBD-infused products, today announced that it is now an approved vendor for Kampgrounds of America (“KOA”(R)) and Yogi Bear’s Jellystone Park(TM) Camp-Resorts. “We are pursuing some exciting growth opportunities in the hospitality segment and are thrilled to announce our newest partnership with two of North America’s leading family camping destination providers,” WTER president and CEO Ricky Wright said in the press release. “There are approximately 82 million camper households in the U.S., and the recent pandemic-related travel limitations are drawing more first-time campers to the activity. Camping and glamping booking services providers are reporting huge spikes in business, with some 400% busier than the same time last year. As such, our timing is perfect, and pursuing unique growth areas in the hospitality and foodservice arena remains a priority. As an approved vendor, our leading brands, Alkaline88 (R), and A88 Infused(TM) flavors, will be available to franchisors of approximately 520 KOA and 81 Jellystone Park Camp-Resort locations. In addition, KOA campgrounds will offer A88CBD(TM) products to adult guests. Our single-serve, eco-friendly and all-natural products are an ideal fit for this segment and will be offered at their retail camp stores and on-site foodservice operations. We believe our products’ availability at these high traffic locations represents a huge growth opportunity and will further enhance the brand equity of our lifestyle products.”

To view the full press release, visit https://ibn.fm/jO46p

About The Alkaline Water Company

Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label: Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in seven unique all-natural flavors with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products includes both the company’s lab-tested, full-spectrum hemp salves, balms, lotions, essential oils and bath salts, along with broad-spectrum hemp beverage shots, powder packs, oil tinctures, capsules and gummies. To learn more about the company, visit www.A88CBD.com and www.TheAlkalineWaterCo.com.

NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://ibn.fm/WTER

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

$SGLB Reports Third Quarter 2020 Financial Results

SANTA FE, NM / October 22, 2020 / Sigma Labs, Inc. (NASDAQ:SGLB) (“Sigma Labs”), a leading developer of quality assurance software for the commercial 3D metal printing industry, reported its financial and operational results for the third quarter ended September 30, 2020.

Key Third Quarter 2020 and Subsequent Operational Highlights

• Appointed Steve Immel to the position of Senior Director Business Development, North America;
  • Responsible for engaging with 3D printer OEMS, additive manufacturers, academic institutions and research organizations to propel Sigma Labs PrintRite3D® in-process quality assurance solutions into production applications; and
  • Veteran of the 3D printing industry having fulfilled leadership roles at 3D Systems, Materialise and Jabil Additive.
• Extended OEM Agreement and completed certification process designating Additive Industries’ MetalFAB1 printers PrintRite3D® Ready:
  • Will begin selling PrintRite3D® Melt-Pool Monitoring solution to new and existing users of MetalFAB1 3D printers; and
  • Reduced post-processing costs, less material waste, and faster part qualification for end users.
• Awarded contract by Major Oil and Gas Services Company:
  • To begin production deployment of PrintRite3D® in-process quality assurance software, following a successful Rapid Test and Evaluation (RTE) program; and
  • Extensive evaluation process involved running PrintRite3D® on an EOS single laser machine and an SLM dual laser machine.
• Awarded Contract From Coherent (NASDAQ: COHR) for New PrintRite3D Lite In-Process Quality Assurance System:
  • Launched its newest product, the PrintRite3D Lite In-Process Quality Assurance (IPQA) system;
  • The PrintRite3D Lite IPQA® system was designed and developed specifically to fulfill the need for melt pool quality monitoring for the small, compact, entry level machines being used in academia, R&D, dental, and industrial small lot production; and
  • PrintRite3D Lite will be available for OEM licensing as well as third party retrofit installations.
• Announced Strategic Alliance with IN4.OS for Factories of the Future:
  • Partnered with IN4.OS to build Smart Factories of the Future to meet the demands of high technology sectors including defense, space, aerospace and life sciences;
  • Provides flexibility in the manufacturing process to build custom mission critical parts on demand, with unprecedented complexity in times of shortages; and
  • IN4.OS will be utilizing DMG MORI’s LASERTEC line of 3D metal printers, which have been designated as PrintRite3D® Ready.
• Expanded market opportunity and announced PrintRite3D for Directed Energy Deposition (DED) additive processes:
  • New partnership with Northwestern University expands in-process quality assurance technology across a broad array of 3D printing processes;
  • DED has been successfully applied in various industries, including aerospace, oil & gas, defense, marine and architecture; and
  • Currently engaged with additional commercial DED machine OEM partners to expand beta testing program.

Management Commentary

“The third quarter of 2020 was about execution and laying the foundation for a successful 2021 and we are very pleased to have made significant progress in each of the strategic initiatives that we established at the beginning of the year,” said Mark K. Ruport, President and Chief Executive Officer of Sigma Labs. “On the financial front, our balance sheet expanded during the third quarter by $3.5 million from the exercise of preferred warrants from our January 2020 private placement of convertible preferred stock and warrants. This, paired with a continued reduction in cash burn, has better positioned Sigma to weather any macro-economic storms that may arise over the coming months and extends our cash runway well into 2021.

“During the third quarter of 2020, we announced a contract with a major oil and gas services company, following a successful Rapid Test and Evaluation (RTE) program. The conversion from our RTE program to beginning production deployment is a testament to the traction our enabling technology is garnering in the additive manufacturing industry. This followed last quarter’s contract with Mitsubishi Heavy Industries, a global leader in engineering and manufacturing to implement PrintRite3D. These large global manufacturers adopting PrintRite3D as their quality assurance system of choice continues to validate Sigma’s technology and the need for a third party, standards-based system that can operate in a heterogeneous 3D printer environment.

“The strategic nature of our agreements with Additive Industries and Coherent combined with our partnership with DMG MORI cannot be overstated. Each provides leverage to our business model, increases our global reach, expands our footprint in the industry and adds more validation to our technology.

“We also expanded our addressable market opportunity with Printrite3D Lite and PriontRite3D DED. We are excited to have Coherent as our initial customer for PrintRite3D Lite and to work with Northwestern University, our initial customer for PrintRite3D DED. Each market offers significant opportunities for revenue growth while extending our IPQA technology across different processes on the manufacturing floor,” continued Ruport.

“As we look into 2021, Sigma Labs will remain laser-focused on building leverage into our business model and expanding our reach and footprint in the industry. Our priorities are: driving multi-unit sales of PrintRite3D Production Series by end users that have validated our technology through the @Sigma RTE program; forming new strategic alliances and OEM contracts with both additive manufacturing hardware and software companies that provide sales leverage and market validation; and continued success with R&D organizations and universities. We look forward to sharing more on our developing story at upcoming investor conferences and virtual roadshows in the fourth quarter of 2020,” concluded Ruport.

Third Quarter 2020 Financial Results

Revenue for the third quarter of 2020 totaled $0.25 million. This compares to revenues of $0.17 million for the third quarter of 2019. The increase in revenue was due to increased PrintRite3D® unit sales, including the first sale of a PrintRite3D Lite® unit during the quarter.

Gross profit for the third quarter of 2020 was $0.15 million as compared to negative $8 thousand in the third quarter of 2019.

Total operating expenses for the third quarter of 2020 were $1.4 million as compared to total operating expenses of $1.6 million for the same period in 2019.

Cash used in operating activities for the three months ended September 30, 2020 totaled $1.2 million compared to $1.8 million in the third quarter of 2019, a decrease of $0.6 million. Cash used in operating activities for the nine months ended September 30, 2020 totaled $3.7 million compared to $4.5 million for the first nine months of 2019. The decrease in year-to-date cash used in 2020 versus 2019 was driven primarily by a $967,161 decrease in net loss.

Net loss for the third quarter of 2020 was $1.2 million, or $(0.42) per share, as compared to a net loss of $1.6 million, or $(1.20) per share, in the third quarter of 2019.

Cash totaled $4.5 million at September 30, 2020, as compared to $2.5 million at June 30, 2020 and $1.1 million at September 30, 2019. The increase in cash during the period was a result of warrant exercises from our January 2020 private placement of convertible preferred stock and warrants.

Third Quarter 2020 Results Conference Call

Sigma Labs President and CEO Mark Ruport and CFO Frank Orzechowski will host the conference call, followed by a question and answer period.

To access the call, please use the following information:

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact MZ Group at 1-949-491-8235.

The conference call will be broadcast live and available for replay at http://public.viavid.com/index.php?id=141888 and via the investor relations section of the Company’s website at www.sigmalabsinc.com.

A replay of the conference call will be available after 7:30 p.m. Eastern time through November 5, 2020.

About Sigma Labs

Sigma Labs Inc. (NASDAQ: SGLB) is a leading provider of quality assurance software to the commercial 3D metal printing industry under the PrintRite3D® brand. Sigma specializes in the development and commercialization of real-time monitoring solutions known as PrintRite3D® for 3D metal advanced manufacturing technologies. PrintRite3D detects and classifies defects and anomalies real-time during the manufacturing process and informs the production manager of quality issues. Sigma Labs believes its software product will be a major catalyst for the acceleration and adoption of 3D metal printing. For more information, please visit www.sigmalabsinc.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors, including, but not limited to, the uncertain effect of the COVID-19 pandemic on the Sigma Labs’ business, results of operations and financial condition, which may cause the Company’s actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Annual Report on Form 10-K (including but not limited to the discussion under “Risk Factors” therein) filed with the SEC on March 24, 2020 and which may be viewed at www.sec.gov.

Investor Contact:
Chris Tyson
Managing Director
MZ Group – MZ North America
949-491-8235
SGLB@mzgroup.us
www.mzgroup.us

Company Contact:
Steven Gersten
Sigma Internal IR
813-334-9745
investors@sigmalabsinc.com

Sigma Labs, Inc.
Condensed Balance Sheets
(Unaudited)

Sigma Labs, Inc.
Condensed Statements of Operations
(Unaudited)

Sigma Labs, Inc.
Condensed Statements of Cash Flows
(Unaudited)

SOURCE: Sigma Labs, Inc.

$UUUU Challenges of Incorporating Electro-Mobility in Mining

Cybin Corp. Appoints New CEO with Impressive Health-Care Expertise

Why Gage Cannabis Co. Is ‘One to Watch’

October 21, 2020